Abstract:<p>Cancer is the second leading cause of human death globally. PI3K/Akt/mTOR signaling is one of the most frequently dysregulated signaling pathways observed in cancer patients that plays crucial roles in promoting tumor initiation, progression and therapy responses. This is largely due to that PI3K/Akt/mTOR signaling is indispensable for many cellular biological processes, including cell growth, metastasis, survival, metabolism, and others. As such, small molecule inhibitors targeting major kinase components of the PI3K/Akt/mTOR signaling pathway have drawn extensive attention and been developed and evaluated in preclinical models and clinical trials. Targeting a single kinase component within this signaling usually causes growth arrest rather than apoptosis associated with toxicity-induced adverse effects in patients. Combination therapies including PI3K/Akt/mTOR inhibitors show improved patient response and clinical outcome, albeit developed resistance has been reported. In this review, we focus on revealing the mechanisms leading to the hyperactivation of PI3K/Akt/mTOR signaling in cancer and summarizing efforts for developing PI3K/Akt/mTOR inhibitors as either mono-therapy or combination therapy in different cancer settings. We hope that this review will facilitate further understanding of the regulatory mechanisms governing dysregulation of PI3K/Akt/mTOR oncogenic signaling in cancer and provide insights into possible future directions for targeted therapeutic regimen for cancer treatment, by developing new agents, drug delivery systems, or combination regimen to target the PI3K/Akt/mTOR signaling pathway. This information will also provide effective patient stratification strategy to improve the patient response and clinical outcome for cancer patients with deregulated PI3K/Akt/mTOR signaling.</p>

Advancements in dual-target inhibitors of PI3K for tumor therapy: Clinical progress, development strategies, prospects

Development of small-molecule inhibitors that target PI3Kβ

Development of small-molecule inhibitors that target PI3K13

PI3K Inhibitors for Cancer Therapy: What Has Been Achieved So Far?

Development of PI3K inhibitors: Advances in clinical trials and new strategies (Review)

PI3K/Akt/mTOR pathway inhibitors in cancer: a perspective on clinical progress.

Targeting PI3K family with small-molecule inhibitors in cancer therapy: current clinical status and future directions

Targeting PI3K in cancer: mechanisms and advances in clinical trials

Small Molecules Targeting Phosphoinositide 3-Kinases

Advances in Subunits of PI3K Class I in Cancer.

Development and Safety of PI3K Inhibitors in Cancer

Targeting the PI3K/AKT signaling pathway in anticancer research: a recent update on inhibitor design and clinical trials (2020–2023)

Design, Synthesis, and Biological Evaluation of Imidazo[1,2-a]pyridine Derivatives as Novel PI3K/mTOR Dual Inhibitors.

Review of research on dual PI3K-mTOR small molecular inhibitors

Design, Synthesis, and Biological Evaluation of Imidazo[1,2-<i>a</i>]pyridine Derivatives as Novel PI3K/mTOR Dual Inhibitors

The present and future of PI3K inhibitors for cancer therapy

Attacking the PI3K/Akt/mTOR signaling pathway for targeted therapeutic treatment in human cancer

Targeting PI3K/Akt signal transduction for cancer therapy

Recent Advances in Dual PI3K/mTOR Inhibitors for Tumour Treatment

Molecular Targeting of the Phosphoinositide-3-Protein Kinase (PI3K) Pathway across Various Cancers

Structure-Based Drug Design and Synthesis of PI3Kα-Selective Inhibitor (PF-06843195)